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with relevant follow up for positive tests. Prior to the test, attenders were given a
questionnaire about their doubt and arguments in relation to the participation
decision, including different willingness-to-pay (WTP) questions. Non-attenders
were mailed a similar questionnaire. RESULTS: 70% responded to the question-
naire, which lead to a study sample of 1,053 attenders and 435 non-attenders.
Among attenders, 5% had doubt about participation and the most frequent argu-
ment was that they did not want to know about the test result. Among non-attend-
ers, 46% would reconsider attendance after further information, the main argu-
ment for doubt being the same as for attenders. Further arguments were self-
perceived low risk and the trouble and costs associated with attending. Attenders
valued the programme significantly higher than non-attenders but this was sensi-
tive to exclusion of bidders who did not pass a simple test for internal consistency
of the reported WTP. Doubt about participation was associated with significantly
lower WTP among attenders whereas the opposite was the case for non-attenders.
Amongst those in doubt, the WTP was the same for attenders and non-attenders.
CONCLUSIONS:Up to half of the non-attenders appeared to have doubt about their
decision, which presents a potential for increasing the participation rate. Non-
attenders in doubt about their participation decision value the programme at a
similar level as attenders in doubt, suggesting that non-attenders in doubt do not
differ significantly in their base-line valuations from those of the individuals in
doubt who choose to attend.
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OBJECTIVES: Generic reference pricing of medicines was introduced in Finland in
April 2009. The system restricts the amount of reimbursement paid to a consumer,
thus creating a financial incentive for the consumer to accept the switch to a
reference priced product. The aim of this study was to assess the impact of refer-
ence pricing on consumer’s choice, and to analyze the factors associated with the
choice of an originator drug priced higher than the reference price.METHODS: The
data used in this study was collected from the Social Insurance Institute=s prescrip-
tion register. Data covers the records of the purchases in five active ingredient
groups (atorvastatin, simvastatin, risperidone, olanzapine, quetiapine) by a sample
population from January 2008 to August 2010. Data includes information of the
consumer’s socio-demographic characteristics and income, and of the prescribed
and purchased product. Logistic regression analysis and logistic multilevel regres-
sion analysis were used to examine the factors associated with a consumer’s orig-
inator drug choice. RESULTS: After the introduction of reference pricing the use of
originator drugs declined but some of the consumers chose originator drugs even
when priced higher than reference price. An important factor explaining the prob-
ability of choosing over reference priced originator drugs is habit, the choice history
of the patient. In some active ingredient groups’ higher age, higher income and
female sex increased the probability of originator drug choice. The right to special
reimbursement mainly lowered the probability. CONCLUSIONS: In earlier studies
it has been shown that some of the consumers have prejudices on generic products
and they want to stick with doctor=s choice of medicine. The results of our study
also indicate that doctor=s primary decision of the prescribed medicine probably
has an influence on some consumers choices and that decision has an important
role in promoting the use of cheaper, generic products.
PCV125
THE INCREASING BURDEN OF ATRIAL FIBRILLATION ON HEALTH CARE IN
SCOTLAND
Choy AM1, Punekar YS2, Keech M3
1Ninewells Hospital and Medical School, Dundee, UK, 2Sanofi-Aventis, Guildford, UK,
3Pharmakos Ltd., St. Albans, UK
OBJECTIVES: Atrial fibrillation (AF) is the most common cardiac arrhythmia in
clinical practice with increasing prevalence in the aging population. The objective
of our study was to evaluate the impact of AF on secondary care costs in Scotland.
METHODS: Patient hospitalisation data collected by the Information and Statistics
Division (ISD) of the Scottish National Health Service (NHS) from 2004 to 2008 were
analysed to estimate the trends in hospital episodes in the 5.2 million population of
Scotland. The associated costs were estimated using the tariff prices in Scotland for
the respective years. RESULTS: Over the 5 year period, the number of patients
hospitalised for AF increased by 21.0% to 26,510 patients in 2008 from 21,907 in
2004, with a total of 162,449 hospital admissions for AF over this period and ac-
counting for 20.8% of total cardiovascular (CV) hospitalisations in 2008. The total
inpatient bed days in 2008 were 394,128; a 14.5% increase during this time, with
mean length of inpatient stay for AF higher than the mean for all cardiovascular
conditions (10.9 vs 8.7). The total cost (inpatient and day cases) attributable to AF
increased from £138.9 million in 2004 to £162.5 million in 2008, accounting for a
quarter (23.8%) of all CV hospital costs in Scotland. Overall, the burden of AF was
higher among women and increased progressively with age. CONCLUSIONS: AF
presents a significant and increasing burden on hospital care in Scotland. As a
proportion of total CV burden, AF accounts for nearly a quarter and is increasing at
a relatively higher rate.
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OBJECTIVES: To evaluate current practice, characteristics of treated population,
utilization of resources and direct medical costs related to anticoagulation treat-
ment in 6 indications in Poland. METHODS: The study consisted of 3 parts: cross-
sectional study (performed in hospitals and open care), retrospective chart review
and experts opinion-based study. The study was carried out between December 20,
2010 and March 15, 2011. Patients data on anticoagulation therapy or with atrial
fibrillation or immobilized were included in cross-sectional part (2021 hospitalized
patients and 4175 monitored in outpatient treatment). Documentation of 1752 pa-
tients treated for stroke, myocardial infraction, coronary artery disease, deep vein
thrombosis, pulmonary embolism or atrial fibrillation or undergoing surgery (e.g.
hip or knee replacement) was included in retrospective chart review. A total of 546
face-to-face interviews with physicians of different specializations (orthopedists,
general and vascular surgeons, cardiologists, neurologists, general practitioners
and rehabilitation therapists) were conducted in opinion-based study. Projection of
treated population was made in order to generalize the results to the whole
country. RESULTS: About 150,000 prescriptions for anticoagulants were made
within 2 weeks of study. Approximately 36,000 patients daily were treated with
anticoagulants in hospitals. The main reason for administrating anticoagulants in
outpatient treatment was primary stroke prevention in patients with atrial fibril-
lation (28%), secondary prevention of venous thromboembolism (18%) and second-
ary stroke prevention in atrial fibrillation (14%). During hospitalization anticoagu-
lants were administered mainly as a prevention of venous thromboembolism in
patients who underwent a surgery (33%), or were immobilized due to other reasons
(17%). Vitamin K antagonists accounted for 65% of market in outpatient practice,
while low-molecular-weight heparins (LMWH) constituted 77% in inpatient
treatment. CONCLUSIONS: Administration of anticoagulants in inpatient treat-
ment is usually surgery-related, while in outpatient treatment the most common
reason is stroke prevention. Oral anticoagulants are usually administrated in out-
patient treatment, while LMWHs are most commonly used in hospitals.
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OBJECTIVES: To assess the time to initiation of therapy with an oral antihypergly-
caemic agent (OAHA) or statin in patients with newly diagnosed type 2 diabetes
mellitus (T2DM). METHODS: In a retrospective US cohort study using the General
Electric electronic medical record database, patients 18 years were included if
they were newly diagnosed with T2DM between January 1, 2004 and December 31,
2005 (index period), with last pre-index A1C 7%, and had not received any anti-
hyperglycaemic agents within the 2 years prior to diagnosis (index date). In addi-
tion, patients were required to be eligible for statin therapy per 2008 American
Diabetes Association recommendations but not on a statin within 1 year prior to
index date. Patients had to have medical records 1 year prior to (baseline) and at
least 2 years after (follow up) the index date. Initiation of OAHA and statin was
determined based on the first prescription record for each therapeutic class.
RESULTS: Of the 2254 patients with newly diagnosed T2DM (58% male), mean age
at index date was 58 years. The most recent mean HbA1c before diagnosis was 8.5%
and mean LDL-cholesterol was 106 mg/dL. Further, 21% of patients had pre-exist-
ing overt CV disease, 40% had dyslipidaemia, 37% were obese, and 11% were smok-
ers. After 2 years of follow up, 48% and 53% of patients initiated an OAHA and
statin, respectively, with 18% initiating both agents on the same day. The median
time from diabetes diagnosis to initiation of OAHA was 119 days and 325 days for
statin initiation. Median time from initiation of OAHA to initiation of statin was 69
days. CONCLUSIONS: Treatment with OAHA and/or statin was suboptimal after
years years in patients with newly diagnosed T2DM who were also eligible for
statin therapy. Of those treated, patients initiated treatment earlier with OAHA
than with statin.
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OBJECTIVES: To describe the resource use and level of anticoagulation control
associated with different patient characteristics within a secondary care anticoag-
ulation service. METHODS: An observational research study was conducted in one
secondary-care anticoagulation service between March and June 2010. Retrospec-
tive data were collected on patient characteristics (age, diagnosis, co-morbidities,
concomitant medications), number of INR (International Normalised Ratio, pro-
thrombin time) visits and time in target range (TTR) from all patients registered
with the service after January 1, 2008 and 3 months before data collection. Data
were analysed by initiation (0-12 weeks after initiation of warfarin) and mainte-
nance ( week 12) phases and correlations run to explore relationships. RESULTS:
Data were collected from 288 patients; mean age 67 years, 54% male. 45% had atrial
fibrillation (AF), 37% were receiving warfarin for venous thromboembolism treat-
ment or prevention (VTE), 18% other reasons (e.g cardiac valves). Mean number of
INR visits was 8.4 during initiation and 1.6 per month during maintenance for
patients with AF and 10.2 and 1.9 respectively for VTE. Mean TTR was 45% during
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